Capital Research Global Investors Has $174.27 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Capital Research Global Investors grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,162,513 shares of the company's stock after buying an additional 25,309 shares during the period. Capital Research Global Investors owned 0.41% of Takeda Pharmaceutical worth $174,272,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in TAK. Blair William & Co. IL lifted its position in Takeda Pharmaceutical by 8.1% in the 4th quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after purchasing an additional 913 shares during the last quarter. Sage Rhino Capital LLC grew its holdings in Takeda Pharmaceutical by 14.9% in the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after buying an additional 1,538 shares in the last quarter. Aaron Wealth Advisors LLC increased its position in Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock valued at $331,000 after acquiring an additional 1,670 shares during the period. OLD Mission Capital LLC boosted its position in Takeda Pharmaceutical by 13.7% during the 4th quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock worth $185,000 after acquiring an additional 1,687 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Takeda Pharmaceutical by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after purchasing an additional 1,770 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Price Performance

NYSE TAK traded down $0.08 on Friday, reaching $15.03. 2,188,219 shares of the stock traded hands, compared to its average volume of 1,973,853. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.37. The company has a market cap of $47.82 billion, a price-to-earnings ratio of 37.58, a P/E/G ratio of 0.24 and a beta of 0.39. The firm's fifty day simple moving average is $14.70 and its 200 day simple moving average is $13.93. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.